The past versus the present, 1980-2004: Reduction of mean initial low-dose, long-term glucocorticoid therapy in rheumatoid arthritis from 10.3 to 3.6 mg/day, concomitant with early methotrexate, with long-term effectiveness and safety of less than 5 mg/day

NeuroImmunoModulation

Volumn 22, Issue , 2014, Pages 89-103

  Pincus, Theodore ^a   Sokka, Tuulikki ^b   Cutolo, Maurizio ^c  

^a RUSH UNIVERSITY   (United States)

^b JYVÄSKYLÄ CENTRAL HOSPITAL   (Finland)

^c UNIVERSITY OF GENOA   (Italy)

Author keywords

Low dose prednisone; Multidimensional health assessment questionnaire; Rheumatoid arthritis

Indexed keywords

METHOTREXATE; PREDNISONE; ANTIARRHYTHMIC AGENT; GLUCOCORTICOID;

ARTICLE; CORTICOSTEROID THERAPY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; LOW DRUG DOSE; META ANALYSIS (TOPIC); OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHEUMATOID ARTHRITIS; ROUTINE ASSESSMENT OF PATIENT INDEX DATA; SYSTEMATIC REVIEW (TOPIC); TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; ARTHRITIS, RHEUMATOID; FEMALE; LONGITUDINAL STUDY; MALE; QUESTIONNAIRE; TREATMENT OUTCOME;

ANTI-ARRHYTHMIA AGENTS; ARTHRITIS, RHEUMATOID; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLUCOCORTICOIDS; HUMANS; LONGITUDINAL STUDIES; MALE; METHOTREXATE; QUESTIONNAIRES; TREATMENT OUTCOME;

EID: 84908582752     PISSN: 10217401     EISSN: 14230216     Source Type: Journal    
DOI: 10.1159/000362735     Document Type: Article

References (100)

1. Hench PS, Kendall EC, Slocumb CH, Polley HF: The effect of a hormone of the adrenal cortex (17-hydroxy-11-dehydrocorticosterone; compound E) and of the pituitary adrenocorticotropic hormone on rheumatoid arthritis. Proc Staff Meet Mayo Clin 1949; 24: 181.
2. Hench PS: The reversibility of certain rheumatic and non-rheumatic conditions by the use of cortisone or of the pituitary adrenocorticotropic hormone. Ann Intern Med 1952; 36: 1-38.
3. Joint Committee of the Medical Research Council and Nuffield Foundation: A comparison of cortisone and aspirin in the treatment of early cases of rheumatoid arthritis. Br Med J 1954; 29: 1223-1227.
4. Polley HF, Slocumb CH, Ward LE, Hench PS: Recognition and treatment of patients with chronic hypercortisonism. Ann Rheum Dis 1955; 14: 416-417.
5. de Andrade JR, McCormick JN, Hill AGS: Small doses of prednisolone in the management of rheumatoid arthritis. Ann Rheum Dis 1964; 23: 158-162.
6. Benedek TG: History of the development of corticosteroid therapy. Clin Exp Rheumatol 2011; 29(5 suppl 68):5-12.
7. Gorter SL, Bijlsma JW, Cutolo M, Gomez- Reino J, Kouloumas M, Smolen JS, et al: Current evidence for the management of rheumatoid arthritis with glucocorticoids: A systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2010; 69: 1010-1014.
8. Smolen JS, Landewe R, Breedveld FC, Buch M, Burmester G, Dougados M, et al: EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014; 73: 492-509.
9. Sokka T, Kautiainen H, Toloza S, Makinen H, Verstappen SMM, Hetland ML, et al: QUESTRA: quantitative clinical assessment of patients with rheumatoid arthritis seen in standard rheumatology care in 15 countries. Ann Rheum Dis 2007; 66: 1491-1496.
10. Sokka T, Toloza S, Cutolo M, Kautiainen H, Makinen H, Gogus F, et al: Women, men, and rheumatoid arthritis: Analyses of disease activity, disease characteristics, and treatments in the QUEST-RA Study. Arthritis Res Ther 2009; 11:R7.
11. Harris ED Jr, Emkey RD, Nichols JE, Newberg A: Low dose prednisone therapy in rheumatoid arthritis: A double blind study. J Rheumatol 1983; 10: 713-721.
12. Yelin E, Meenan R, Nevitt M, Epstein W: Work disability in rheumatoid arthritis: effects of disease, social, and work factors. Ann Intern Med 1980; 93: 551-556.
13. Pincus T, Callahan LF, Sale WG, Brooks AL, Payne LE, Vaughn WK: Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years. Arthritis Rheum 1984; 27: 864-872.
14. Scott DL, Grindulis KA, Struthers GR, Coulton BL, Popert AJ, Bacon PA: Progression of radiological changes in rheumatoid arthritis. Ann Rheum Dis 1984; 43: 8-17.
15. Kirwan JR: The effects of glucocorticoids on joint destruction in rheumatoid arthritis. N Engl J Med 1995; 333: 142-146.
16. Boers M, Verhoeven AC, Markusse HM, van de Laar MAFJ, Westhovens R, van Denderen JC, et al: Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997; 350: 309-318.
17. van Everdingen AA, Jacobs JWG, van Reesema DRS, Bijlsma JWJ: Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects. Ann Intern Med 2002; 136: 1-12.
18. Svensson B, Boonen A, Albertsson K, van der Heijde D, Keller C, Hafstrom I: Low-dose prednisolone in addition to the initial diseasemodifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: A two-year randomized trial. Arthritis Rheum 2005; 52: 3360-3370.
19. Wassenberg S, Rau R, Steinfeld P, Zeidler H: Very low-dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years: A multicenter, doubleblind, placebo-controlled trial. Arthritis Rheum 2005; 52: 3371-3380.
20. Buttgereit F, Doering G, Schaeffler A, Witte S, Sierakowski S, Gromnica-Ihle E, et al: Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA- 1): A double-blind, randomised controlled trial. Lancet 2008; 371: 205-214.
21. Pincus T, Swearingen CJ, Luta G, Sokka T: Efficacy of prednisone 1-4 mg/day in patients with rheumatoid arthritis: A randomised, double-blind, placebo controlled withdrawal clinical trial. Ann Rheum Dis 2009; 68: 1715- 1720.
22. Montecucco C, Todoerti M, Sakellariou G, Scire CA, Caporali R: Low-dose oral prednisone improves clinical and ultrasonographic remission rates in early rheumatoid arthritis: results of a 12-month open-label randomised study. Arthritis Res Ther 2012; 14:R112.
23. Bakker MF, Jacobs JW, Welsing PM, Verstappen SM, Tekstra J, Ton E, et al: Low-dose prednisone inclusion in a methotrexatebased, tight control strategy for early rheumatoid arthritis: A randomized trial. Ann Intern Med 2012; 156: 329-339.
24. Buttgereit F, Mehta D, Kirwan J, Szechinski J, Boers M, Alten RE, et al: Low-dose prednisone chronotherapy for rheumatoid arthritis: A randomised clinical trial (CAPRA-2). Ann Rheum Dis 2013; 72: 204-210.
25. Kirwan JR, Bijlsma JW, Boers M, Shea BJ: Effects of glucocorticoids on radiological progression in rheumatoid arthritis. Cochrane Database Syst Rev 2007:CD006356.
26. Danowski TS, Bonessi JV, Sabeh G, Sutton RD, Webster MW Jr, Sarver ME: Probabilities of pituitary-adrenal responsiveness after steroid therapy. Ann Intern Med 1964; 61: 11-26.
27. Wood JB, Frankland AW, James VH, Landon J: A rapid test of adrenocortical function. Lancet 1965; 1: 243-245.
28. Daly JR, Myles AB, Bacon PA, Beardwell CG, Savage O: Pituitary adrenal function during corticosteroid withdrawal in rheumatoid arthritis. Ann Rheum Dis 1967; 26: 18-25.
29. LaRochelle GE Jr, LaRochelle AG, Ratner RE, Borenstein DG: Recovery of the hypothalamic- pituitary-adrenal (HPA) axis in patients with rheumatic diseases receiving low-dose prednisone. Am J Med 1993; 95: 258-264.
30. Saag KG, Koehnke R, Caldwell JR, Brasington R, Burmeister LF, Zimmerman B, et al: Low dose long-term corticosteroid therapy in rheumatoid arthritis: An analysis of serious adverse events. Am J Med 1994; 96: 115-123.
31. Wei L, MacDonald TM, Walker BR: Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med 2004; 141: 764-770.
32. Laan RF, van Riel PL, van de Putte LB, van Erning LJ, van't Hof MA, Lemmens JA: Lowdose prednisone induces rapid reversible axial bone loss in patients with rheumatoid arthritis: A randomized, controlled study. Ann Intern Med 1993; 119: 963-968.
33. Pincus T, Brooks RH, Callahan LF: Prediction of long-term mortality in patients with rheumatoid arthritis according to simple questionnaire and joint count measures. Ann Intern Med 1994; 120: 26-34.
34. Wolfe F, Mitchell DM, Sibley JT, Fries JF, Bloch DA, Williams CA, et al: The mortality of rheumatoid arthritis. Arthritis Rheum 1994; 37: 481-494.
35. Hoffmeister RT: Methotrexate therapy in rheumatoid arthritis: 15 years experience. Am J Med 1983; 75(suppl 6A):69-73.
36. Hoffmeister RT: Methotrexate in rheumatoid arthritis (abstract). Arthritis Rheum 1972; 15(suppl):S114.
37. Weinblatt ME, Coblyn JS, Fox DA, Fraser PA, Holdsworth DE, Glass DN, et al: Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med 1985; 312: 818-822.
38. Pincus T, Marcum SB, Callahan LF: Longterm drug therapy for rheumatoid arthritis in seven rheumatology private practices. II. Second- line drugs and prednisone. J Rheumatol 1992; 19: 1885-1894.
39. Pincus T, Gibson KA, Castrejón I: Update on methotrexate as the anchor drug for rheumatoid arthritis. Bull Hosp Jt Dis 2013; 71(suppl 1):S9-S19.
40. Yazici Y, Sokka T, Kautiainen H, Swearingen C, Kulman I, Pincus T: Long term safety of methotrexate in routine clinical care: discontinuation is unusual and rarely the result of laboratory abnormalities. Ann Rheum Dis 2005; 64: 207-211.
41. Pincus T, Castrejon I, Sokka T: Long-term prednisone in doses of less than 5 mg/day for treatment of rheumatoid arthritis: personal experience over 25 years. Clin Exp Rheumatol 2011; 29(5 suppl 68):S130-S138.
42. Pincus T, Sokka T, Castrejón I, Cutolo M: Decline of mean initial prednisone dosage from 10.3 to 3.6 mg/day to treat rheumatoid arthritis between 1980 and 2004 in one clinical setting, with long-term effectiveness of dosages less than 5 mg/day. Arthritis Care Res 2013; 65: 729-736.
43. Sokka T, Pincus T: Ascendancy of weekly lowdose methotrexate in usual care of rheumatoid arthritis from 1980 to 2004 at two sites in Finland and the United States. Rheumatology (Oxford) 2008; 47: 1543-1547.
44. Pincus T, Swearingen CJ: The HAQ compared with the MDHAQ: 'keep it simple, stupid' (KISS), with feasibility and clinical value as primary criteria for patient questionnaires in usual clinical care. Rheum Dis Clin North Am 2009; 35: 787-798.
45. Pincus T, Swearingen C, Wolfe F: Toward a multidimensional health assessment questionnaire (MDHAQ): Assessment of advanced activities of daily living and psychological status in the patient friendly health assessment questionnaire format. Arthritis Rheum 1999; 42: 2220-2230.
46. Pincus T, Sokka T, Kautiainen H: Further development of a physical function scale on a multidimensional health assessment questionnaire for standard care of patients with rheumatic diseases. J Rheumatol 2005; 32: 1432-1439.
47. Pincus T, Yazici Y, Bergman MJ: RAPID3, an index to assess and monitor patients with rheumatoid arthritis, without formal joint counts: similar results to DAS28 and CDAI in clinical trials and clinical care. Rheum Dis Clin North Am 2009; 35: 773-778.
48. Sackett DL, Rosenberg WM, Gray JM, Haynes RB, Richardson WS: Evidence based medicine: What it is and what it isn't: it's about integrating individual clinical expertise and the best external evidence. Br Med J 1996; 312: 71-72.
49. Feinstein AR: An additional basic science for clinical medicine. II. The limitations of randomized trials. Ann Intern Med 1983; 99: 544- 550.
50. Pincus T: Limitations of randomized controlled clinical trials to recognize possible advantages of combination therapies in rheumatic diseases. Semin Arthritis Rheum 1993; 23(suppl 1):2-10.
51. Pincus T, Callahan LF: Prognostic markers of activity and damage in rheumatoid arthritis: Why clinical trials and inception cohort studies indicate more favorable outcomes than studies of patients with established disease. Br J Rheumatol 1995; 34: 196-199.
52. Pincus T, Stein CM: Why randomized controlled clinical trials do not depict accurately long-term outcomes in rheumatoid arthritis: some explanations and suggestions for future studies. Clin Exp Rheumatol 1997; 15(suppl 17):S27-S38.
53. Kaptchuk TJ: The double-blind, randomized, placebo-controlled trial: gold standard or golden calf? J Clin Epidemiol 2001; 54: 541-549.
54. Pincus T, Sokka T: Should contemporary rheumatoid arthritis clinical trials be more like standard patient care and vice versa? Ann Rheum Dis 2004; 63(suppl II):ii32-ii39.
55. Pincus T, Sokka T: Clinical trials in rheumatic diseases: designs and limitations. Rheum Dis Clin North Am 2004; 30: 701-704.
56. Moses LE: The series of consecutive cases as a device for assessing outcomes of intervention. N Engl J Med 1984; 311: 705-710.
57. Lau J, Ioannidis JP, Schmid CH: Summing up evidence: one answer is not always enough. Lancet 1998; 351: 123-127.
58. Psaty BM, Koepsell TD, Lin D, Weiss NS, Siscovick DS, Rosendaal FR, et al: Assessment and control for confounding by indication in observational studies. J Am Geriatr Soc 1999; 47: 749-754.
59. Landewe RB: The benefits of early treatment in rheumatoid arthritis: confounding by indication, and the issue of timing. Arthritis Rheum 2003; 48: 1-5.
60. OCEBM Levels of Evidence Working Group: The Oxford 2011 Levels of Evidence. Oxford, Centre for Evidence-Based Medicine, 2011. http://www.cebm.net/index.aspx?o=5653.
61. Howick J: The Philosophy of Evidence-Based Medicine. Oxford, Wiley-Blackwell, 2011.
62. Smith GCS, Pell JP: Parachute use to prevent death and major trauma related to gravitational challenge: systematic review of randomised controlled trials. BMJ 2003; 327: 1459-1461.
63. Glasziou P, Chalmers I, Rawlins M, McCulloch P: When are randomised trials unnecessary? Picking signal from noise. BMJ 2007; 334: 349-351.
64. Aronson JK, Hauben M: Anecdotes that provide definitive evidence. BMJ 2006; 333: 1267- 1269.
65. Wolfe F, Hawley DJ: Remission in rheumatoid arthritis. J Rheumatol 1985; 12: 245-252.
66. Pincus T, Sokka T, Kautiainen H: Patients seen for standard rheumatoid arthritis care have significantly better articular, radiographic, laboratory, and functional status in 2000 than in 1985. Arthritis Rheum 2005; 52: 1009-1019.
67. Pincus T, Stein CM, Wolfe F: 'No evidence of disease' in rheumatoid arthritis using methotrexate in combination with other drugs: A contemporary goal for rheumatology care? Clin Exp Rheumatol 1997; 15: 591-596.
68. Pincus T, Sokka T, Stein CM: Are long-term very low doses of prednisone for patients with rheumatoid arthritis as helpful as high doses are harmful? Ann Intern Med 2002; 136: 76- 78.
69. Silman A, Davies P, Currey HLF, Evans SJW: Is rheumatoid arthritis becoming less severe? J Chronic Dis 1983; 36: 891-897.
70. Spector TD, Hart DJ, Powell RJ: Prevalence of rheumatoid arthritis and rheumatoid factor in women: evidence for a secular decline. Ann Rheum Dis 1993; 52: 254-257.
71. Porter DR, Capell HA, McInnes I, Munro R, Madhok R, Hunter JA et al: Is rheumatoid arthritis becoming a milder disease? Or are we starting second-line therapy in patients with milder disease? Br J Rheumatol 1996; 35: 1305-1308.
72. Welsing PMJ, Fransen J, van Riel PLCM: Is the disease course of rheumatoid arthritis becoming milder? Time trends since 1985 in an inception cohort of early rheumatoid arthritis. Arthritis Rheum 2005; 52: 2616-2624.
73. Da Silva JA, Jacobs JW, Kirwan JR, Boers M, Saag KG, Ines LB, et al: Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. Ann Rheum Dis 2006; 65: 285-293.
74. Huscher D, Thiele K, Gromnica-Ihle E, Hein G, Demary W, Dreher R, et al: Dose-related patterns of glucocorticoid-induced side effects. Ann Rheum Dis 2009; 68: 1119-1124.
75. Pincus T: Rheumatoid arthritis: disappointing long-term outcomes despite successful short-term clinical trials. J Clin Epidemiol 1988; 41: 1037-1041.
76. Fleming TR, DeMets DL: Surrogate end points in clinical trials: Are we being misled? Ann Intern Med 1996; 125: 605-613.
77. Pincus T: Limitations of randomized clinical trials in chronic diseases: explanations and recommendations. Adv Mind Body Med 2002; 18: 14-21.
78. Fransen J, van Riel PLCM: Are better endpoints and better design of clinical trials needed? Best Pract Res Clin Rheumatol 2004; 18: 97-109.
79. Pincus T, Yazici Y, Sokka T: Are excellent systematic reviews of clinical trials useful for patient care? Nat Clin Pract Rheumatol 2008; 4: 294-295.
80. Pincus T, Furer V, Sokka T: Underestimation of the efficacy, effectiveness, tolerability, and safety of weekly low-dose methotrexate in information presented to physicians and patients. Clin Exp Rheumatol 2010; 28(5 suppl 61):S68-S79.
81. Felson DT, Anderson JJ, Meenan RF: The comparative efficacy and toxicity of secondline drugs in rheumatoid arthritis: results of two metaanalyses. Arthritis Rheum 1990; 33: 1449-1461.
82. Donahue KE, Gartlehner G, Jonas DE, Lux LJ, Thieda P, Jonas BL, et al: Systematic review: comparative effectiveness and harms of disease- modifying medications for rheumatoid arthritis. Ann Intern Med 2008; 148: 124-134.
83. Pincus T: Limitations to standard randomized controlled clinical trials to evaluate combination therapies in rheumatic diseases. Agents Actions Suppl 1993; 44: 83-91.
84. Sokka T, Pincus T: Eligibility of patients in routine care for major clinical trials of anti-tumor necrosis factor alpha agents in rheumatoid arthritis. Arthritis Rheum 2003; 48: 313-318.
85. Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al: Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomized phase III trial. Lancet 1999; 354: 1932-1939.
86. Sokka T, Pincus T: Most patients receiving routine care for rheumatoid arthritis in 2001 did not meet inclusion criteria for most recent clinical trials or American College of Rheumatology criteria for remission. J Rheumatol 2003; 30: 1138-1146.
87. Möttönen T, Hannonen P, Leirisalo-Repo M, Nissilä M, Kautiainen H, Korpela M, et al: Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: A randomised trial. FIN-RACo trial group. Lancet 1999; 353: 1568-1573.
88. Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R, et al: Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): A single-blind randomised controlled trial. Lancet 2004; 364: 263-269.
89. Goekoop-Ruiterman YPM, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJSM, Hazes JMW, et al: Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): A randomized, controlled trial. Arthritis Rheum 2005; 52: 3381-3390.
90. Verstappen SMM, Jacobs JWG, van der Veen MJ, Heurkens AHM, Schenk Y, ter Borg EJ, et al: Intensive treatment with methotrexate in early rheumatoid arthritis: Aiming for remission - Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis 2007; 66: 1443-1449.
91. Hetland ML, Stengaard-Pedersen K, Junker P, Lottenburger T, Hansen I, Andersen LS, et al: Aggressive combination therapy with intra- Articular glucocorticoid injections and conventional disease-modifying anti-rheumatic drugs in early rheumatoid arthritis: second- year clinical and radiographic results from the CIMESTRA study. Ann Rheum Dis 2008; 67: 815-822.
92. Tymms K, Zochling J, Scott J, Bird P, Burnet S, de JJ, et al: Barriers to optimal disease control for rheumatoid arthritis patients with moderate and high disease activity. Arthritis Care Res (Hoboken) 2014; 66: 190-196.
93. Braun J, Pincus T, Cronstein B: Methotrexate in rheumatic diseases. Clin Exp Rheumatol 2010; 28(5 suppl 61).
94. Cronstein BN: Molecular therapeutics: methotrexate and its mechanism of action. Arthritis Rheum 1996; 39: 1951-1960.
95. Chan ESL, Cronstein BN: Molecular action of methotrexate in inflammatory diseases. Arthritis Res 2002; 4: 266-273.
96. Pincus T, Huizinga TWJ, Yazici Y: N-of-1 trial of low-dose methotrexate and/or prednisolone in lieu of anti-CCP, MRI, or ultrasound, as first option in suspected rheumatoid arthritis? J Rheumatol 2007; 34: 250-252.
97. Sokka T, Pincus T: Erythrocyte sedimentation rate, C-reactive protein, or rheumatoid factor are normal at presentation in 35%- 45% of patients with rheumatoid arthritis seen between 1980 and 2004: Analyses from Finland and the United States. J Rheumatol 2009; 36: 1387-1390.
98. Abelson B, Sokka T, Pincus T: Declines in erythrocyte sedimentation rates in patients with rheumatoid arthritis over the second half of the 20th century. J Rheumatol 2009; 36: 1596-1599.
99. den Uyl D, Ter Wee M, Boers M, Kerstens P, Voskuyl A, Nurmohamed M, et al: A noninferiority trial of an attenuated combination strategy ('COBRA-light') compared to the original COBRA strategy: clinical results after 26 weeks. Ann Rheum Dis 2014; 73: 1071-1078.
100. Leirisalo-Repo M, et al: Infliximab for 6 months added on combination therapy in early rheumatoid arthritis: 2-year results from an investigator-initiated, randomised, double-blind, placebo-controlled study (the NEO-RACo Study). Ann Rheum Dis 2013; 72: 851-857.